Science

Kidney Cancer

Jun 20, 2025, 14:47

Bevacizumab Plus Erlotinib Showed Strong Antitumor Activity In Papillary Kidney Cancer – NEJM

NEJM shared a post on X:

“In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity.

The likelihood of a response was higher in hereditary cases than in sporadic ones.

Full study results.”

Title: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Authors: Ramaprasad Srinivasan, Sandeep Gurram, Eric A. Singer, Abhinav Sidana, Munjid Al Harthy, Mark W. Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy D. Vocke, Christopher J. Ricketts, Heidi H. Kong, Edward W. Cowen, Ashkan A. Malayeri, Joanna H. Shih, Maria J. Merino, W. Marston Linehan

You can read the Full Article on The New England Journal of Medicine

Bevacizumab Plus Erlotinib Showed Strong Antitumor Activity In Papillary Kidney Cancer - NEJM

Francesco Massari, Associate Professor at University of Bologna and Medical Oncologist focused on Genitourinary Cancer at The University Hospital of Bologna IRCCS, shared this post, adding:

“An important trial for a rare RCC.

Another good news for our patients.”

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Science

OncoDaily

Science

Bevacizumab Plus Erlotinib Showed Strong Antitumor Activity In Papillary Kidney Cancer – NEJM

“In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity.

The likelihood of a response was higher in hereditary cases than in sporadic ones.

Full study results.”

“An important trial for a rare RCC.

Another good news for our patients.”